Aprogen Pharmaceuticals Inc Total Assets
Aprogen Pharmaceuticals Inc total assets. Based on the latest financial reports, Aprogen Pharmaceuticals Inc (003060) holds total assets worth ₩603.42 Billion KRW (≈ $408.93 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Aprogen Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Aprogen Pharmaceuticals Inc (2009–2024)
Total assets of Aprogen Pharmaceuticals Inc from 2009 to 2024. This chart illustrates how Aprogen Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See Aprogen Pharmaceuticals Inc (003060) stock price for real-time trading data and today's change.
Aprogen Pharmaceuticals Inc - Asset Composition Analysis
Aprogen Pharmaceuticals Inc Total Assets Breakdown (December 2024)
Aprogen Pharmaceuticals Inc total assets breakdown as of December 2024. Aprogen Pharmaceuticals Inc's total assets of ₩603.42 Billion consist of 19.5% current assets and 80.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.1% |
| Accounts Receivable | ₩16.61 Billion | 2.8% |
| Inventory | ₩52.29 Billion | 8.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩5.12 Billion | 0.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Aprogen Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 003060 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aprogen Pharmaceuticals Inc's current assets represent 19.5% of total assets in 2024, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2024, down from 5.0% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 10.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 8.9% of total assets.
Aprogen Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Aprogen Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Aprogen Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.86 | 1.15 | 38.79 |
| Quick Ratio | 0.60 | 0.70 | 37.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-30.43 Billion | ₩19.35 Billion | ₩327.85 Billion |
Aprogen Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Aprogen Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.33 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.3% |
| Total Assets | ₩590.98 Billion |
| Market Capitalization | $175.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aprogen Pharmaceuticals Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Aprogen Pharmaceuticals Inc's assets grew by 0.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Aprogen Pharmaceuticals Inc (2009–2024)
The table below shows the annual total assets of Aprogen Pharmaceuticals Inc from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩590.98 Billion ≈ $400.50 Million |
+0.27% |
| 2023-12-31 | ₩589.40 Billion ≈ $399.43 Million |
-13.85% |
| 2022-12-31 | ₩684.14 Billion ≈ $463.63 Million |
+11.31% |
| 2021-12-31 | ₩614.62 Billion ≈ $416.52 Million |
-0.11% |
| 2020-12-31 | ₩615.31 Billion ≈ $416.99 Million |
+68.45% |
| 2019-12-31 | ₩365.28 Billion ≈ $247.55 Million |
+68.29% |
| 2018-12-31 | ₩217.06 Billion ≈ $147.10 Million |
+37.14% |
| 2017-12-31 | ₩158.27 Billion ≈ $107.26 Million |
+22.99% |
| 2016-12-31 | ₩128.69 Billion ≈ $87.21 Million |
+51.01% |
| 2015-12-31 | ₩85.22 Billion ≈ $57.75 Million |
+0.46% |
| 2014-12-31 | ₩84.83 Billion ≈ $57.49 Million |
+8.39% |
| 2013-12-31 | ₩78.26 Billion ≈ $53.04 Million |
-15.93% |
| 2012-12-31 | ₩93.08 Billion ≈ $63.08 Million |
-19.99% |
| 2011-12-31 | ₩116.33 Billion ≈ $78.84 Million |
+47.82% |
| 2010-12-31 | ₩78.70 Billion ≈ $53.33 Million |
+16.35% |
| 2010-09-30 | ₩67.64 Billion ≈ $45.84 Million |
+14.51% |
| 2009-12-31 | ₩59.07 Billion ≈ $40.03 Million |
-- |
About Aprogen Pharmaceuticals Inc
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.